Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir.

@article{Canducci2011CrossresistancePO,
  title={Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir.},
  author={Filippo Canducci and Elisa Rita Ceresola and Enzo Boeri and Vincenzo Spagnuolo and Francesca Cossarini and Antonella Castagna and Adriano Lazzarin and Massimo Clementi},
  journal={The Journal of infectious diseases},
  year={2011},
  volume={204 11},
  pages={1811-5}
}
Novel integrase inhibitors are in advanced clinical development, and cross-resistance data are needed to consider the possibility to plan a sequential usage within this class of antiretroviral drugs. Ex vivo phenotypic assays were conducted on 11 wild-type and 27 fully replicating recombinant viruses obtained from 11 patients failing previous raltegravir-containing regimens. Dolutegravir maintained its activity in vitro on viruses with mutations in position 143 and 155. However, viruses with… CONTINUE READING